Syndax Pharmaceuticals Ownership | Who Owns Syndax Pharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

Syndax Pharmaceuticals Ownership Summary


Syndax Pharmaceuticals is owned by 17.47% institutional investors, 1.72% insiders, and 80.81% retail investors. Blackrock funding, inc. /de is the largest institutional shareholder, holding 9.53% of SNDX shares. Vanguard Health Care Inv is the top mutual fund, with 3.50% of its assets in Syndax Pharmaceuticals shares.

SNDX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockSyndax Pharmaceuticals17.47%1.72%80.81%
SectorHealthcare Stocks 35.58%11.87%52.55%
IndustryBiotech Stocks 35.75%11.83%52.41%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock funding, inc. /de8.25M9.53%$192.82M
Kynam capital management, lp8.05M9.29%$188.07M
Blackrock7.91M9.28%$162.33M
Vanguard group6.23M7.19%$130.90M
Goldman sachs group5.00M5.77%$116.72M
State street4.43M5.11%$103.49M
Deerfield management company, l.p. (series c)3.78M4.36%$88.30M
Adage capital partners gp3.31M3.84%$50.95M
Eversept partners, lp2.89M3.33%$67.41M
Kingdon capital management2.50M2.89%$58.40M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Kynam capital management, lp8.05M11.60%$188.07M
Aisling capital management lp1.32M6.46%$30.76M
Kingdon capital management2.50M6.41%$58.40M
Knott david m jr422.00K5.87%$9.86M
Stempoint capital lp1.22M5.52%$28.40M
Catalio capital management, lp1.04M5.09%$24.38M
Lion point capital, lp36.00K5.03%$840.96K
Eversept partners, lp2.89M3.55%$67.41M
Palo alto investors lp864.99K3.09%$20.21M
Prosight management, lp770.00K2.95%$17.99M

Top Buyers

HolderShares% AssetsChange
Deerfield management company, l.p. (series c)3.78M1.04%3.78M
Adage capital partners gp3.31M0.08%1.88M
Vanguard group6.23M0.00%1.09M
Orbimed advisors962.30K0.45%962.30K
Vanguard fiduciary trust600.52K0.00%600.52K

Top Sellers

HolderShares% AssetsChange
Point72 asset management1.99M0.06%-2.90M
Avoro capital advisors---2.27M
Bvf inc/il---1.88M
Balyasny asset management126.14K0.00%-1.69M
Sofinnova investments---1.52M

New Positions

HolderShares% AssetsChangeValue
Deerfield management company, l.p. (series c)3.78M1.04%3.78M$88.30M
Orbimed advisors962.30K0.45%962.30K$22.48M
Vanguard fiduciary trust600.52K0.00%600.52K$14.03M
Ikarian capital333.73K0.52%333.73K$5.13M
Essex investment management198.99K0.74%198.99K$4.65M

Sold Out

HolderChange
Tfc financial management-1.00
Nelson, van denburg & campbell wealth management group-13.00
Riggs asset managment-26.00
Svb wealth-27.00
Stephens consulting-30.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 202694-61.94%15,133,904-84.85%170.13%45-62.18%23-70.13%
Dec 31, 2025166-32.52%53,238,549-47.45%610.45%78-39.06%46-34.29%
Sep 30, 20252385.78%101,267,9708.78%1171.01%1236.03%6913.11%
Jun 30, 2025232-101,730,1911.68%1170.86%116-3.33%651.56%
Mar 31, 20252332.19%100,944,7752.97%1170.90%119-7.03%6510.17%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Health Care Inv2.99M3.50%-
Vanguard Total Stock Mkt Idx Inv2.80M3.17%46.05K
Vanguard US Total Market Shares ETF2.60M3.01%4.69K
State Street® SPDR® S&P® Biotech ETF2.61M2.95%-25.85K
iShares Russell 2000 ETF2.02M2.28%17.01K
SPDR® S&P Biotech ETF1.54M1.78%3.43K
Eventide Healthcare & Life Sciences I1.24M1.40%249.06K
Hood River Small-Cap Growth Instl1.21M1.37%-
Vanguard Institutional Extnd Mkt Idx Tr980.08K1.11%7.91K
BNP Paribas US Small Cap ClassicC954.94K1.08%29.16K

Recent Insider Transactions


DateNameRoleActivityValue
Feb 09, 2026Metzger Michael A Chief Executive OfficerSell$360.82K
Feb 09, 2026Goldan Keith A. Chief Financial OfficerSell$71.71K
Feb 06, 2026Metzger Michael A Chief Executive OfficerSell$152.84K
Feb 06, 2026Goldan Keith A. Chief Financial OfficerSell$42.93K
Sep 08, 2025Metzger Michael A Chief Executive OfficerSell$2.58M

Insider Transactions Trends


DateBuySell
2026 Q1-4
2025 Q4--
2025 Q3-6
2025 Q24-
2025 Q1-4

SNDX Ownership FAQ


Who Owns Syndax Pharmaceuticals?

Syndax Pharmaceuticals shareholders are primarily institutional investors at 17.47%, followed by 1.72% insiders and 80.81% retail investors. The average institutional ownership in Syndax Pharmaceuticals's industry, Biotech Stocks , is 35.75%, which Syndax Pharmaceuticals falls below.

Who owns the most shares of Syndax Pharmaceuticals?

Syndax Pharmaceuticals’s largest shareholders are Blackrock funding, inc. /de (8.25M shares, 9.53%), Kynam capital management, lp (8.05M shares, 9.29%), and Blackrock (7.91M shares, 9.28%). Together, they hold 28.10% of Syndax Pharmaceuticals’s total shares outstanding.

Does Blackrock own Syndax Pharmaceuticals?

Yes, BlackRock owns 9.28% of Syndax Pharmaceuticals, totaling 7.91M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 162.33M$. In the last quarter, BlackRock increased its holdings by 354.33K shares, a 4.69% change.

Who is Syndax Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Kynam capital management, lp is Syndax Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 11.60% of its assets in 8.05M Syndax Pharmaceuticals shares, valued at 188.07M$.

Who is the top mutual fund holder of Syndax Pharmaceuticals shares?

Vanguard Health Care Inv is the top mutual fund holder of Syndax Pharmaceuticals shares, with 3.50% of its total shares outstanding invested in 2.99M Syndax Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools